BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32215902)

  • 1. Criteria-Based Imaging and Response Evaluation of Lymphoma 20 Years After Cheson: What is New?
    Skusa C; Weber MA; Böttcher S; Thierfelder KM
    Rofo; 2020 Jul; 192(7):657-668. PubMed ID: 32215902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria.
    Winkelmann M; Blumenberg V; Rejeski K; Bücklein VL; Ingenerf M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
    Cancer Imaging; 2023 May; 23(1):44. PubMed ID: 37189191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
    Younes A; Hilden P; Coiffier B; Hagenbeek A; Salles G; Wilson W; Seymour JF; Kelly K; Gribben J; Pfreunschuh M; Morschhauser F; Schoder H; Zelenetz AD; Rademaker J; Advani R; Valente N; Fortpied C; Witzig TE; Sehn LH; Engert A; Fisher RI; Zinzani PL; Federico M; Hutchings M; Bollard C; Trneny M; Elsayed YA; Tobinai K; Abramson JS; Fowler N; Goy A; Smith M; Ansell S; Kuruvilla J; Dreyling M; Thieblemont C; Little RF; Aurer I; Van Oers MHJ; Takeshita K; Gopal A; Rule S; de Vos S; Kloos I; Kaminski MS; Meignan M; Schwartz LH; Leonard JP; Schuster SJ; Seshan VE
    Ann Oncol; 2017 Jul; 28(7):1436-1447. PubMed ID: 28379322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Staging and Treatment Response Evaluation in Malignant Lymphomas - Czech Lymphoma Study Group Recommendations According to Criteria Revised in 2014 (Lugano Classification)].
    Sýkorová A; Pytlík R; Móciková H; Belada D; Benešová K; Papajík T; Janíková A; Šálek D; Procházka V; Vokurka S; Campr V; Klener P; Kubáčková K; Trněný M
    Klin Onkol; 2016; 29(4):295-302. PubMed ID: 27534788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hybrid imaging in lymphoma].
    Mayerhöfer ME; Haug A
    Radiologe; 2020 May; 60(5):376-385. PubMed ID: 32296856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
    Wahl RL; Jacene H; Kasamon Y; Lodge MA
    J Nucl Med; 2009 May; 50 Suppl 1(Suppl 1):122S-50S. PubMed ID: 19403881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RECIL versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients.
    Berzaczy D; Haug A; Staber PB; Raderer M; Kiesewetter B; Jaeger U; Kornauth C; Simonitsch-Klupp I; Mayerhoefer ME
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response Evaluation Criteria in Solid Tumors (RECIST) and PET Response Criteria in Solid Tumors (PERCIST) for response evaluation of the neck after chemoradiotherapy in head and neck squamous cell carcinoma.
    Kishikawa T; Suzuki M; Takemoto N; Fukusumi T; Michiba T; Hanamoto A; Tanaka H; Tatsumi M; Isohashi F; Seo Y; Tamari K; Ogawa K; Inohara H
    Head Neck; 2021 Apr; 43(4):1184-1193. PubMed ID: 33368784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson.
    Fournier L; Ammari S; Thiam R; Cuénod CA
    Diagn Interv Imaging; 2014; 95(7-8):689-703. PubMed ID: 24951349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD
    Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response Assessment Criteria and Their Applications in Lymphoma: Part 2.
    Moghbel MC; Mittra E; Gallamini A; Niederkohr R; Chen DL; Zukotynski K; Nadel H; Kostakoglu L
    J Nucl Med; 2017 Jan; 58(1):13-22. PubMed ID: 27879369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revised staging system for malignant lymphoma based on the Lugano classification.
    Munakata W; Terauchi T; Maruyama D; Nagai H
    Jpn J Clin Oncol; 2019 Oct; 49(10):895-900. PubMed ID: 31504700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
    Juweid ME; Mueller M; Alhouri A; A-Risheq MZ; Mottaghy FM
    Cancer; 2021 Oct; 127(20):3727-3741. PubMed ID: 34286864
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
    Barrington SF; Mikhaeel NG; Kostakoglu L; Meignan M; Hutchings M; Müeller SP; Schwartz LH; Zucca E; Fisher RI; Trotman J; Hoekstra OS; Hicks RJ; O'Doherty MJ; Hustinx R; Biggi A; Cheson BD
    J Clin Oncol; 2014 Sep; 32(27):3048-58. PubMed ID: 25113771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis.
    Salvatore B; Fonti R; De Renzo A; Pellegrino S; Ferrara IL; Mainolfi CG; Marano L; Selleri C; Pane F; Del Vecchio S; Pace L
    Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):219-225. PubMed ID: 29697219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
    Karls S; Shah H; Jacene H
    Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials.
    Kostakoglu L; Martelli M; Sehn LH; Davies A; Trněný M; Herold M; Vitolo U; Hiddemann W; Trotman J; Knapp A; Mattiello F; Nielsen TG; Sahin D; Sellam G; Ward C; Younes A
    EJHaem; 2023 Nov; 4(4):1042-1051. PubMed ID: 38024624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging for Oncologic Response Assessment in Lymphoma.
    Kulkarni NM; Pinho DF; Narayanan S; Kambadakone AR; Abramson JS; Sahani DV
    AJR Am J Roentgenol; 2017 Jan; 208(1):18-31. PubMed ID: 27786547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET/CT: appropriate application in lymphoma.
    Wang X
    Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.